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Objectives: Since the introduction of non-vitamin-K-antagonist oral anticoagu-
lants (OACs), an additional option for stroke prevention in patients with atrial fibril-
lation (AF) compared to vitamin-K-antagonists (VKAs) is available. The objective 
of this study was to assess patients’ preferences regarding the attributes of these 
different treatment options. MethOds: We conducted a multicenter study among 
randomly selected physicians who were asked to recruit AF patients. Patients’ 
preferences were assessed by computer-assisted telephone interviews. We used a 
Discrete-Choice-Experiment (DCE) with four treatment dependent attributes (need 
of bridging: yes/no, interactions with food/nutrition: yes/no, need of INR controls/
dose adjustment: yes/no, frequency of intake: once/twice daily) and one compara-
tor attribute (distance to practitioner: < 1km/> 15km). Preferences measured in the 
interviews were analyzed descriptively and based on a conditional logistic regres-
sion model. Results: A total of 140 AF patients (age: 74.0±8.5 years; 57.0% male; 
mean CHA2DS2-VASc: 6.1±1.1; current medication: 27.1% rivaroxaban, 71.4% VKA, 
1.4% other) could be interviewed. Regardless of type of medication, patients signifi-
cantly preferred the attributes’ level (in order of patients’ importance) “once daily” 
for “frequency of intake” (binary-coded: once = 1 vs. twice = 0; Coefficient = 0.954; 
p< 0.001), “no” for “interaction with food/nutrition” (yes vs. no; -0.842; p< 0.001), “no” 
for “bridging necessary” (yes vs. no; -0.656; p< 0.001) and “≤ 1 km” for “distance to 
practitioner” (≤ 1 km vs. > 15 km; 0.644; p< 0.001). However, for the attribute “need of 
INR controls/dose adjustment” (yes vs. no; 0.020; p= 0.808) no significant preference 
in favour of one of the options are shown. cOnclusiOns: In our analyses, “once 
daily frequency of intake” was the most important attribute for patients’ choice 
followed by “no interactions with food/nutrition” and “no bridging necessary”. Thus, 
patients with AF seem to prefer treatment options which are easier to administer.
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Objectives: There are few studies in Spain about outcomes at 1-year in terms of 
health-related quality of life (HRQoL) in patients hospitalized by heart failure (HF). 
The main objective of the present study was to evaluate changes in HRQoL from 
baseline to 1-year post discharge in patients with HF through two questionnaires, 
SF-12 and Minnesota Living with Heart Failure questionnaire (MLHFQ). MethOds: 
This has been a prospective study with 502 patients admitted by HF in Basque 
Country (Spain). Patients completed questionnaires during their hospitalization and 
at 1-year. The MLHFQ is a specific instrument which has 21 items with an overall 
scale, physical (8 items) and emotional (5 items) subscales. MlhFQ items are scoring 
from 0 (best) to 5 (worst). Total score ranges from 0 to 105, physical domain from 
0 to 40 and emotional from 0 to 25. SF-12 has two dimensions, Physical Summary 
Score (PCS) and Mental Summary Score (MSC) which scores range from 0 (worst) 
to 100 (best). We have used general linear model to study gains in each dimension 
adjusted by baseline score, age, gender and hospital readmissions in the previous 
6 months. Results: Mean age was 76.7 (SD= 10.4), there were a 56.1% of men and 
20.3% of readmissions in the previous six months. Regarding both questionnaires 
and dimensions, baseline status influence in gains, the worse the baseline the more 
the gains. Likewise men have greater gains and patients readmitted lower in all 
domains. Age has an influence in MLHFQ physical domain and PCS. cOnclusiOns: 
Adjusted by baseline score and readmissions, men have greater improvements in 
all domains of MLHFQ and SF-12. On the other hand, the younger the patients the 
higher the improvement is, in physical domains however age does not have any 
influence in psychological domains.
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Objectives: To identify and summarize the key characteristics, strengths, and 
weaknesses of available patient-reported outcome (PRO) measures assessing treat-
ment satisfaction and health-related quality of life (HRQOL) related to anticoagula-
tion therapy in patients with atrial fibrillation, including evaluating how well the 
measures meet current regulatory guidance requirements in Europe and the United 
States. MethOds: Publications describing the development, validation, or use of 
PRO instruments in patients using anticoagulant therapy were identified through 
a comprehensive literature review. Several sources (PubMed, Patient-Reported 
Outcome and Quality of Life Instruments Database [PROQOLID], and ClinicalTrials. 
org) were reviewed to identify instruments. The development process and meas-
urement properties (internal consistency and test-retest reliability, convergent and 
divergent construct validity, known-groups validity, and responsiveness) of the iden-
tified instruments were compared. Results: Five measures assessing anticoagu-
self-reported adherence results and any of the 4 factor scores. cOnclusiOns: 
This study provides BMQ factor scores for urban black HTN patients and insight 
into how experiences of patient’s parents can be used to target increased per-
ception of anti-hypertensive medication necessity and reduce patient-specific 
medication harm concerns.
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Objectives: To investigate the living and employment situation of patients after 
stroke, and examine whether this differs by degree of disability. MethOds: We 
conducted an observational retrospective study among 569 post-stroke patients 
and examined changes in employment and living situation. The investigational 
period was divided into 3 intervals: < 3,3-6 and > 6 months after stroke. All patients 
had their mRS (modified Rankin Score, ranging from 0 full health to 5 severely 
dependent) measured at 3 months after stroke, plus an additional mRS assessment 
if their stroke was more than 6 months ago. Patients were recruited in 10 regional 
and university hospitals across Belgium using a convenience sample stratified by 
mRS. Results: Before their stroke the majority of patients lived at home (99%) 
despite the fact that 13% had a previous stroke. At 3 months after stroke an associa-
tion was found between the time spent in an inpatient care facility (hospital, reha-
bilitation facility, nursing home) and the mRS (p< 0.0001 Weibull survival analysis, 
average inpatients days were 9.2, 14.1, 27.7, 53.4, 67.0 and 73.4 for mRS 0-5 respec-
tively). Between 3 and 6 months after stroke on average 7% of patients were staying 
in a rehabilitation facility and 5% in a nursing home; these were mostly patients 
with mRS > = 3. After six months all patients returned home, except patients with 
mRS4 (36% home) and mRS5 (38% home). Before stroke 70% of patients were retired; 
in those working before their stroke, 16-20% patients in mRS categories 0-2 were 
working again compared to none in mRS category 3-5, of which 14% took early 
retirement or leave of absence. cOnclusiOns: Experiencing a mild stroke will 
not affect the patient’s employment and living situation beyond the short term; 
however suffering a severe stroke is likely to lead to significant changes in place of 
residence and occupation.
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Objectives: Evaluate validity and reliability of the UISESS-B oral health ques-
tionnaire in a Mexican diabetic, systemic hypertension and obese patients in the 
primary health care level. MethOds: Were studied 105 subjects with diabetes, 
systemic hypertension and/or over-weigh-obesity in the context of a diabetic’s 
control group in the Instituto Mexicano del Seguro Social. Was applied an oral 
health questionnaire named UISESS-B previously validated. The instrument is 
divided in three main areas: oral health care habits, oral health and nutrition 
related habits, and oral health care related symptoms and signs. ResultsConstruct 
validity was confirmed by the correct compilation of the items included in the 
two main constructs: habits and perceptions each one including specific multi-
item questionnaires (correlation coefficients ranged from 0.30 to 0.80, P>0.001); 
the reliability was confirmed by the internal consistency (Cronbach alpha: 0.55 
for the construct habits and 0.71 for the construct perceptions). cOnclusiOns: 
The UISESS-B questionnaire shows significant validity and reliability, suggesting 
its use as an instrument useful to be used as a patient reported outcome in oral 
health in patients with chronic diseases.
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Objectives: Many years ago, cardiologists developed on the basis of the 
Framingham study an “arterial age” which is very useful to sensitize patients to their 
cardiovascular risk. The purpose of the study was to develop a “venous age” to make 
people more aware of their venous disease and to better adhere to lifestyle improve-
ment and venous disease treatments. MethOds: The score calculation was based 
on an international epidemiological study conducted in 24 countries in the daily 
practice or general practitioners. The data base included patients with or without 
venous disease, whatever the reason for which they were consulting and whatever 
the level of their venous disease which was systematically described according the 
elements of the international CEAP classification. Results: The study covers 124 
235 patients aged of 52 among whom 69.4% were female. Among them 18.8% had no 
sign of venous disease (C0), 22.9% had only functional symptoms (C0s), 40.6% had 
Telangiectasies or reticular veins, 34.8% varicose, 24.9% edema, 14.0% skin changes, 
7.3 Healed ulcers and 4.3% active ulcers. The statistical analysis has determined 
the number of years which must be added to the real age to get the “venous age” 
by comparison of the age of somebody who has no venous functional symptoms 
or physical signs. The results provide that number for women and men according 
the different venous symptoms and sign they present. cOnclusiOns: This first 
attempt of creating a “venous age” will be certainly improved in the next future, 
using more complex analysis based on risk factors or other criteria, but it seems 
already efficient to make people aware of their venous risk and to better adhere to 
lifestyle improvement and venous disease treatments.
